CSF3 and acute graft versus host disease: In the multivariate analysis, administration of G‐CSF was significantly associated with a higher risk of grades II–IV acute GVHD across all graft types (HR 1.24, 95% CI 1.06–1.44, p = .005 for BMT; HR 1.27, 95% CI 1.07–1.52, p = .006 for PBSCT; HR 1.21, 95% CI 1.01–1.43, p = .030 for CBT) (Table S1).